ENDONOVO THERAPEUTICS, INC. Balance Sheet
ENDV|9 years of annual SEC 10-K data (FY2011-FY2022)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 9 fiscal years. All figures from audited SEC 10-K filings.
ENDONOVO THERAPEUTICS, INC. had $1M in total assets with negative shareholders' equity of $32M as of FY2022. Total debt stood at $7M as of FY2022.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 | FY2014 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | - | $85.9K | $13.4K | $18.9K | $379.2K | $55.5K | $41.5K | $988 | $69.7K |
| Accounts Receivable | - | $944 | $942 | $22.7K | $3.3K | - | - | - | $1.4K |
| Current Assets | $15.8K | $94.9K | $46.2K | $62.6K | $382.5K | $302.9K | $377.7K | $3.0K | $71.1K |
| PP&E (Net) | - | - | $1.6K | $5.9K | $6.7K | $15.8K | $31.7K | $42.6K | $2.2K |
| Total Assets | $1.3M | $2.0M | $2.6M | $3.3M | $4.2M | $318.7K | $409.4K | $45.6K | $73.3K |
| Current Liabilities | $33.4M | $17.7M | $16.8M | $23.6M | $15.5M | $8.7M | $9.5M | $4.6M | $1.3K |
| Total Debt | $7.2M | $7.3M | $6.8M | $6.9M | $8.2M | $3.2M | $28.6K | $1.6M | - |
| Shareholders' Equity | -$32.2M | -$15.8M | -$14.4M | -$20.5M | -$11.4M | -$8.6M | -$9.3M | -$4.7M | $72.0K |